Connectivity alterations in dopaminergic and cholinergic networks mediate cognitive performance in patients with Parkinson’s disease: a resting-state fMRI study
Objective: To explore changes in resting-state fMRI (rs-fMRI) functional connectivity networks in PD patients, in areas with prominent dopaminergic and cholinergic innervation. Background: The pathophysiology…Glymphatic system activity in Parkinson’s disease: diffusion tensor image analysis along the perivascular space (DTI‑ALPS)
Objective: We examined the activity of the glymphatic system in patients with Parkinson’s disease using diffusion tensor image analysis along the perivascular space (DTI-ALPS). Background:…Preserved white matter microstructure in Parkinson’s disease patients with levodopa-induced dyskinesia: Evaluation by neurite orientation dispersion and density imaging (NODDI)
Objective: Brain microstructure alteration using MRI in Parkinson's disease (PD) have not been well studied. We analysis the white matter alterations in Parkinson’s disease with…Longitudinal Change of Substantia Nigra Hyperechogenicity in Parkinson’s Disease Cohort
Objective: To analyze whether the size of SN+ is differentially affected depending on disease duration. Secondly to analyze the interaction between a range of clinical…Mindfulness Based Stress Reduction in People with Parkinson’s Disease and their Carepartners
Objective: To assess the feasibility and impact of mindfulness based stress reduction (MBSR) on people with Parkinson’s disease (PD) and their carepartners. Background: Non-motor symptoms…Prevalence and associated risk factors of early morning off among the patients with Parkinson’s disease in China
Objective: To explore the prevalence and associated risk factors of early morning off (EMO) among outpatients with Parkinson’s disease (PD) in China. Background: PD is…Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study
Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients
Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment
Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…
- « Previous Page
- 1
- …
- 181
- 182
- 183
- 184
- 185
- …
- 405
- Next Page »